Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
863.4 DKK | -0.09% | -4.70% | +11.84% |
Feb. 27 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
Feb. 14 | COLOPLAST : Q1 24: Many more positives beyond the margin beat |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 36.22 and 31.19 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.76% | 27.91B | B+ | ||
-32.98% | 2.95B | B- | ||
-17.23% | 2.47B | C+ | ||
+6.12% | 2.22B | - | A- | |
-1.11% | 1.91B | B | ||
-12.82% | 1.84B | - | - | |
-7.22% | 1.4B | B | ||
-0.38% | 1.26B | - | ||
+4.01% | 1.13B | - | ||
+14.59% | 1.13B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COLO B Stock
- Ratings Coloplast A/S